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Abstract
Objective: To determine whether liver fat percent (LFP) is associated with the metabolic syndrome independently of 
visceral fat area (VFA).
Methods: 43 High-risk vascular patients not on lipid-lowering therapy were evaluated for the Adult Treatment Panel III 
(ATPIII) metabolic syndrome criteria and underwent magnetic resonance imaging (MRI) to quantify VFA and 
subcutaneous fat area (SFA) at the L4-L5 disc and liver magnetic resonance spectroscopy (MRS) to quantify LFP. 
Comparisons: 1. Baseline differences in patients with and without the metabolic syndrome 2. Forward binary logistic 
regression analysis of predictors of the metabolic syndrome with VFA, SFA and LFP as independents 3. Correlates of LFP.
Results: 43 patients were included in analysis. Patients with metabolic syndrome had greater VFA, SFA and LFP than 
patients without the metabolic syndrome (all p < 0.01). Of VFA, SFA and LFP, only LFP was associated with the diagnosis 
of the metabolic syndrome on forward binary logistic regression with an OR of 1.17 per 1% increase in LFP (p = 0.015). 
A 4% LFP threshold identified the metabolic syndrome with 84% sensitivity and 82% specificity. LFP correlated with 
waist circumference (r = 0.768), HDL-cholesterol (r = -0.342), triglyceride (r = 0.369), fasting glucose (r = 0.584) and the 
QUICK Index of insulin sensitivity (r = -0.679) (all p < 0.05)
Conclusions: LFP is associated with the metabolic syndrome and renders the current gold standard of VFA redundant 
in this analysis. This measure of obesity-related cardiovascular risk requires further validation and evaluation in a 
prospective cohort.
Background
In patients with established vascular disease, as in healthy
patients, the diagnosis of the metabolic syndrome por-
tends an increased risk of cardiovascular events and an
increased risk of developing type 2 diabetes mellitus [1-
4]. Large population studies utilizing computed tomogra-
phy (CT) showed visceral fat area (VFA) at the umbilicus
to be a superior determinant of metabolic risk factors and
the metabolic syndrome than the subcutaneous fat area
(SFA) after correction for body mass index (BMI) and
waist circumference [5,6]. VFA is the 'gold standard' for
quantifying obesity-related cardiovascular risk and has
been independently linked to the development of coro-
nary artery disease while SFA has not been shown to
carry prognostic significance [7]. With the increasing use
of magnetic resonance imaging (MRI) in lieu of CT for
metabolic risk assessment, liver fat percent measured by
magnetic resonance spectroscopy (MRS) has also
emerged as a significant correlate of metabolic risk fac-
tors [8]. The potential utility of liver fat percent measured
by MRS is highlighted by the finding of patients with
'metabolically-benign' obesity; i.e. obese patients with
normal insulin sensitivity and lower liver fat percentages
compared to insulin-resistant obese individuals [9]. This
suggests that obese patients with low levels of liver fat
may not have metabolic risk factors despite larger
amounts of visceral fat compared to lean individuals. We
hypothesized that liver fat percent (LFP) determined by
MRS is associated with cardiometabolic risk factors inde-
pendently and would render VFA redundant in predict-
ing metabolic syndrome in a patients with vascular
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disease. Given the prognostic significance of the meta-
bolic syndrome in patients with vascular disease, we eval-
uated the association of VFA, SFA and LFP with
metabolic syndrome in a high-risk vascular cohort. We
sought to identify a useful cut-off value of LFP which
would identify patients with the metabolic syndrome,
independently of other measures of obesity and the cur-
rent gold standard measure of VFA.
Methods and Procedures
Study Population
Eligible patients for this study had coronary artery dis-
e a s e  ( C A D ) ,  i s c h e m i c  s t r o k e  o r  C A D  r i s k - e q u i v a l e n t s .
Eligible patients had to have at least one of the following:
1. CAD (positive angiogram or history of myocardial
infarction) 2. peripheral vascular disease (ABI <0.9 or his-
tory of lower limb revascularization for atherosclerosis)
3. abdominal aortic aneurysm 4. carotid atherosclerosis
with >50% narrowing 5. type II diabetes with age >50 and
3 additional risk factors (male sex, albuminuria, hyper-
tension, HDL-C <40 mg/dl, TG >150 mg/dl, LDL-C >100
mg/dl, current smoking, diabetes duration >20 years) or
6. ischemic stroke. Study participants were in a clinically
stable condition and were recruited from the vascular
surgery outpatient department at the Royal Brisbane &
Women's Hospital (RBWH). The study subjects were not
taking lipid-lowering therapy at time of recruitment.
Patient Data
Patient demographic information was collected including
age, sex, qualifying criterion, self-reported race, current
medications, alcohol intake, blood pressure, anti-hyper-
tensive medication use, height, weight, waist and hip cir-
cumferences. Metabolic syndrome was defined as per the
Adult Treatment Panel III (ATP III) criteria [10]. Fasting
blood samples were analyzed for baseline lipids, glucose
and insulin. Fasting lipid profile and glucose were deter-
mined using standard hospital methods. Insulins were
measured by Chemilumnescent Immunoassay on a Beck-
man Coulter D × I800 as per the manufacturer's instruc-
tions. To determine insulin sensitivity, we used the
Quantitative insulin sensitivity check index (QUICK
Index) since this a superior linear correlate (r~0.8-0.9) of
the reference standard glucose clamp than the Homeo-
stasis model assessment (HOMA) model [11,12].
MRI Measurement of Abdominal Fat Areas
MR imaging was performed with a Siemens Trio 3 T MRI
system (Erlangen, Germany) using standard array coils
with the subject supine. Breath-hold FISP images were
centered on the L4-L5 intervertebral disc using standard
localizer images with the following parameters: TR = 4
ms, TE = 2 ms, number of slices = 12, slice thickness = 8
mm, image matrix 256 × 256, field-of-view = 500 × 500
mm. The 4 slices that were best aligned with the L4-L5
disc (19, 20), were analyzed by a single operator (MRH)
using the polygon region of interest in Escape Medical
Viewer v3.2 to define visceral fat area (VFA) and subcuta-
neous fat area (SFA) as described previously [13]. Briefly,
VFA and SFA were measured by fitting a spline curve to
points on the border of the subcutaneous and visceral
regions. Nonfat regions within the visceral region were
also outlined with a spline fit and subtracted from the
total visceral region.
MRS measurement of Liver Fat Percent
Single voxel spin echo based PRESS spectra were used to
measure liver fat using a Siemens Trio 3 T MRI system
(Erlangen, Germany) using standard array coils with the
subject supine as we have previously described [14,15].
Briefly, a voxel was positioned within the liver using stan-
dard localizer images, avoiding obvious vessels with the
following parameters: TR = 2 sec, TE = 30 ms, voxel size
20 × 20 × 20 mm, 4 averages. The spectrum was acquired
during a single breathhold. Spectra were processed using
the standard Siemens software. Peak quantification was
performed using the Siemens peak fitting package. The
average liver fat content derived from the voxel was
expressed as a percentage using the formula (CH2  +
CH3)/(H2O + CH2 + CH3) ×100. We have previously cor-
related fat content determined with this protocol with
intrahepatocellular lipid content on liver biopsy (r = 0.93)
[15]. Liver fat percent measurements were highly repro-
ducible with a coefficient of variation of 3.5%.
Statistical Methods
The baseline characteristics of the included patients were
summarized and the diagnosis of the metabolic syn-
drome as per the Adult Treatment Panel III (ATP III) cri-
teria [10] was determined for each patient. We compared
patients with and without the metabolic syndrome for
various metabolic parameters and imaging parameters.
We compared the means of continuous variables with a
2-tailed Student's t test for normally distributed variables,
and with the Mann-Whitney U test for non-normally dis-
tributed variables. Categorical variables were analyzed
with the chi-square test or Fisher exact test. We then used
forward LR binary logistic regression to identify indepen-
dent predictors of patients having the diagnosis of the
metabolic syndrome. Candidate variables selected for
logistic regression modeling were the magnetic reso-
nance variables of adiposity VFA, SFA and LFP. Variables
were only entered into the model if the p-value of the
score statistic was less than the entry value of 0.05. Wald
statistics and odds ratios were reported for variables in
the final model and the overall model assessed the c-sta-
tistic for predicting the diagnosis of the metabolic syn-
drome. ROC curves were used to identify an optimal LFPHoenig et al. Nutrition & Metabolism 2010, 7:50
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associated with the metabolic syndrome with acceptable
sensitivity and specificity. In order to determine corre-
lates of LFP, we undertook univariate correlation with the
metabolic syndrome criteria and insulin sensitivity (the
QUICK Index) as independents and LFP as the depen-
dent variable. The QUICK Index of insulin sensitivity for
each subject with insulin and glucose data was calculated
as 1/[log (fasting insulin, μU/ml) + log (fasting glucose,
mg/dl)] [11]. Variables that correlated with LFP with a
Spearman's p < 0.05 were subjected to stepwise multivari-
ate linear regression and the R2 change calculated with
the addition of any variable to the model. To remove the
influence of multicollinearity from the multiple regres-
sion model, variance-inflation factors (VIFs) were deter-
mined and variables with a VIF >4.0 were removed from
the model. Residuals from the regression model were
graphically examined. All analyses were done with statis-
tics software (SPSS 16).
Ethics Approval
This study is approved by the RBWH research ethics
committee (2005/006A) and all study participants gave
informed consent.
Results
4 3  p a t i e n t s  w e r e  e n r o l l e d  i n  t h i s  M R I  s t u d y .  B a s e l i n e
characteristics, including components of the metabolic
syndrome, baseline lipid panel, insulin and QUICK Index
of insulin sensitivity are shown in Table 1. The differences
between the patients with and without the Metabolic
Syndrome are summarized in Table 2 below and show the
expected differences in various metabolic parameters.
Patients with metabolic syndrome had greater amounts
of VFA, SFA and LFP compared to patients without the
metabolic syndrome (p < 0.01). In order to determine
which of these MRI or MRS-derived parameters is most
strongly associated with the metabolic syndrome, we sub-
jected the outcome of metabolic syndrome to binary
logistic regression analysis with VFA, SFA and LFP as
independents. On logistic regression, only liver fat
remained in the model with no contribution from VFA or
SFA; beta 0.15, Wald's statistic 5.9, OR 1.17, p = 0.015.
Thus, the current gold standard for assessing obesity-
related cardiovascular risk is redundant when LFP is con-
sidered as a covariate. Each increase in LFP by 1% is asso-
ciated with an odds ratio for metabolic syndrome of 1.17.
The overall c-statistic for LFP in identifying the metabolic
syndrome was 0.92 (p < 0.001) and in our sample a liver
fat percent of >4.0% identified the metabolic syndrome
with 84% sensitivity and 82% specificity.
Despite the criticism of the label of metabolic syn-
drome as being no greater than a sum of risk factors, it
remains a clinically-useful label denoting an increased
cardiovascular risk. However, given reports of metaboli-
cally-benign obesity [9] and the belief that insulin resis-
tance drives the increased risk of cardiovascular events in
obese individuals [16], we assessed the utility of LFP >4%
in identifying insulin-resistant patients. We compared
the QUICK Index of insulin sensitivity in patients with an
LFP >4% and <4% and found that patients with LFP >4%
were significantly more insulin resistant (lower QUICK
Index score) than those with an LFP <4% p = 0.001 indi-
cating that LFP >4% can identify an insulin-resistant pop-
ulation. Next, we sought to confirm the association
between LFP and metabolic indicators of risk by correlat-
Table 1: Patient Characteristics of Patients Included in the 
Analysis
Mean ± SD or n (%)
Age 70 ± 8
Males 35 (81)
Females 8 (19)
Race
White 42 (98)
Non-White 1 (2)
Height (cm) 172 ± 10
Weight (kg) 79 ± 19
Body Mass Index 26 ± 5
Diabetic, n (%) 10 (23)
Metabolic Syndrome (ATPIII), n (%) 22 (53)
Waist (cm) 101 ± 16
Fasting Glucose (mg/dl) 112 ± 40
HDL Cholesterol (mg/dl) 44 ± 17
Triglycerides (mg/dl) 142 ± 74
Systolic Blood Pressure (mmHg) 142 ± 19
Diastolic Blood Pressure (mmHg) 72 ± 9
Average Number of ATP III Criteria 2.7 ± 1.5
Daily Intake of Alcohol (standard 
drinks) Fasting Insulin (mU/L)
1.4 ± 1.8 7 ± 4
QUICK Index .25 ± .03
Visceral Fat Area (cm2) 203 ± 111
Subcutaneous Fat Area (cm2) 240 ± 113
Liver fat Percentage 6.6 ± 6.3
Qualifying Criteriona
Coronary Artery Disease 10 (24)
Peripheral Vascular Disease 23 (55)
Carotid Atherosclerosis >50% 12 (29)
Abdominal Aortic Aneurysm 10 (24)
Ischemic Stroke 8 (19)
Diabetes 10 (24)
aPatients frequently had >1 inclusion criterionHoenig et al. Nutrition & Metabolism 2010, 7:50
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ing the LFP to each of the metabolic syndrome criteria
and the QUICK Index. The QUICK Index and all the
metabolic syndrome criteria, except for the hypertension
criterion, were significant correlates of liver fat percent as
shown in Table 3. On stepwise multivariate analysis of the
significant univariate correlates as independents and LFP
as the dependent variable, only waist circumference is
retained in the model with an R2 of 0.6, p < 0.001. Hence,
waist circumference is an important determinant of LFP
but does not explain all the variation in LFP. There was no
correlation of LFP with the number of standard alcoholic
beverages consumed daily by the study participants (r = -
0.156, p = 0.364).
Discussion
We have shown that liver fat percent is associated with
the metabolic syndrome independently of visceral fat area
in high-risk vascular patients with each percent increase
in liver fat percentage being associated with an odds ratio
of 1.17 of having the metabolic syndrome. This is the first
head-to-head comparison of these two obesity-related
cardiovascular risk measures and in our cohort, visceral
fat area was a redundant predictor of the metabolic syn-
drome. A cut-off of 4% liver fat identified patients with
the metabolic syndrome with an 84% sensitivity and 82%
specificity. Patients with >4% liver fat had significantly
lower QUICK Insulin sensitivity indices than patients
with <4% liver fat which is consistent with this threshold
Table 2: Characteristics of the Patients with and Without the Metabolic Syndrome
Variable Mean ± SD or n (% of Patients) P value MetSyn vs Without MetSyn
With MetSyn, n = 23 Without MetSyn, n = 20
Number of ATPIII Criteria 3.9 ± 0.7 1.3 ± 0.7 <0.001
Waist (cm) 110 ± 10 91 ± 15 <0.001
HDL-C (mg/dl) 39 ± 18 50 ± 15 0.007
TG (mg/dl) 177 ± 81 102 ± 38 <0.001
Fasting Glucose (mg/dl) 127 ± 50 96 ± 8 0.001
Hypertension, n (%) 17 (74) 10 (50) 0.065
Diabetic, n (%) 10 (43) 0 (0) 0.001
Male, n (%) 19 (83) 16 (80) 0.83
Age 69 ± 7 69 ± 10 0.75
Body Mass Index 29 ± 4 23 ± 3 <0.001
Percentage Liver fat 10.4 ± 6.5 2.4 ± 2.1 <0.001
Visceral Fat Area (cm2) 263 ± 113 134 ± 53 <0.001
Subcutaneous Fat Area (cm2) 282 ± 116 191 ± 91 0.007
Fasting Insulin (mU/L) 9.3 ± 4.9 4.9 ± 2.7 0.001
QUICK Index of Insulin sensitivity 0.242 ± 0.031 0.263 ± 0.26 0.001Hoenig et al. Nutrition & Metabolism 2010, 7:50
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being able to identify insulin-resistant patients. Liver fat
percent correlates with insulin sensitivity and all compo-
nents of the metabolic syndrome except for hypertension.
On multivariate regression, waist circumference is the
only significant determinant of percent liver fat (R2 of 0.6,
p < 0.001).
The association of LFP with the metabolic syndrome is
a clinically-significant one since the metabolic syndrome
in patients with established vascular disease identifies a
cohort at an increased risk of cardiovascular events [1-4].
Indeed, liver fat percent has been shown to be greater in
obese insulin-resistant patients vs obese insulin-sensitive
patients (10.5% vs 5.6%) with the obese insulin-sensitive
patients having a carotid intima-media thickness compa-
rable to healthy normal weight individuals [9]. Hence,
while the definition of obesity has evolved from weight to
body mass index and more recently waist circumference
and subsequently visceral fat area, liver fat percent may
represent the future determinant of obesity-related car-
diovascular risk assessment. Indeed, it is possible that
obese patient with higher amount of visceral fat area but
low liver fat percent may have a cardiovascular event rate
comparable to normal-weight individuals. While our data
are encouraging in showing that liver fat percent may bet-
ter identify the at-risk patient than visceral fat area, our
data set is small and cross-sectional. A large prospective
cohort is required to determine if liver fat percent is inde-
pendently associated with cardiovascular events. One
limitation of this test is the availability of MRI; however,
from a pragmatic perspective, such a measure would be
preferable to visceral fat area since liver fat percent is eas-
ier to measure and does not require tracing of fat areas on
abdominal MRI slices. Further, it would be valuable to
validate liver fat percent as a measure of obesity-related
cardiovascular risk in various ethnic groups since Asians,
in particular, are prone to cardiovascular disease and dia-
betes at lower waist circumference or body mass index
than Europids [17,18]. In summary, we have shown liver
fat percent to be associated with the metabolic syndrome
independently of visceral fat area. Our results suggest
that this measure requires further validation as a maker
of obesity-related cardiovascular risk and assessment in
prospective cohort studies.
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